EcoDrugPlus

Histone Deacetylase 2

Ensembl ID : ENSEEEG00000005962
Gene Symbol: HDAC2
4 Cross references
205 Possible Orthologues:

Histone Deacetylase 4

Ensembl ID : ENSEEEG00000012099
Gene Symbol: HDAC4
2 Cross references
202 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSEEEG00000017366
Gene Symbol: HDAC5
4 Cross references
196 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSEEEG00000003118
Gene Symbol: HDAC6
3 Cross references
182 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSEEEG00000010605
Gene Symbol: HDAC8
4 Cross references
206 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSEEEG00000017215
Gene Symbol: HCN4
4 Cross references
211 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSEEEG00000016229
Gene Symbol: HCN4
4 Cross references
219 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSEEEG00000008468
Gene Symbol: HCRTR2
4 Cross references
201 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSEEEG00000002650
Gene Symbol: IKBKB
2 Cross references
198 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSEEEG00000005547
Gene Symbol: INPP5D
4 Cross references
216 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSEEEG00000013256
Gene Symbol: INSRA
2 Cross references
231 Possible Orthologues:

Insulin Receptor B

Ensembl ID : ENSEEEG00000011399
Gene Symbol: INSRB
4 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).